July 3, 2024
Crypto

Solana Soars 16% Over 7 Days, Outpacing Bitcoin And Ethereum Over ETF Application Momentum — More Applications To Follow? – Emeren Group (NYSE:SOL)


Solana SOL/USD is on the ascendancy amid fresh applications for the first-ever exchange-traded funds tracking the coin’s spot price in the U.S.

What Happened: The fifth-largest digital asset by market cap spiked 6.4% in the last 24 hours, exceeding the gains of Bitcoin BTC/USD and Ethereum ETH/USD

Solana’s trading volume jumped 50% to $1.68 billion, becoming the third-most traded cryptocurrency, excluding stablecoins, in the last 24 hours.

See Also: ‘Rich Dad Poor Dad’ Author Robert Kiyosaki Questions Bitcoin ETFs’ Authenticity: ‘ETFs Are Fake Gold, Silver, Or Bitcoin’

Solana’s weekly gains increased to 16.59%, one of the strongest among large-cap cryptocurrencies. 

Why It Matters: The latest bullish impetus has been provided by applications for spot ETFs for Solana. 

After VanEck kicked off the race last week by becoming the first asset manager to file for such an investment avenue in the U.S., 21Shares followed suit with its application with the SEC.

Spot cryptocurrency ETFs in the U.S. have been broadly successful, with Bitcoin BTC/USD recording a 36% jump in price after its funds started trading in early January. 

Ethereum ETH/USD is also days away from getting listed in U.S. exchanges, pending approval from the SEC. 

Price Action: At the time of writing, SOL was exchanging hands at $147.55, surging 6.4% in the last 24 hours, according to data from Benzinga Pro

Read Next: SEC Files Lawsuit Against Consensys Over Unregistered Brokerage Activities

Market News and Data brought to you by Benzinga APIs



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. View more
Accept
Decline